ECDO-EATI Conference will provide an excellent opportunity to promote your company as a sponsor and exhibitor. It offers a great experience for interacting with an international group of researchers, scientists and influencial industry representatives.
The European Cell Death Organization ECDO and the European Academy of Tumor Immunology EATI will celebrate their joint annual meeting on June 28-30 at the Pasteur Institute, Paris, France. EATI has been branding its annual meeting as « Paris Immuno-Oncology » PIO.
The topic of the ECDO2023/PIO2023 conference – a fully « real » event without any virtual component – will be « Cell death in oncopharmacology and oncoimmunology ». The first day of this high-carat meeting will be devoted to cell death mechanisms, the second to immunogenic cell death, and the third to recent developments in the ever-expanding field of immuno-oncology.
The first day of the meeting will be devoted to cell death mechanisms in human pathophysiology, especially cancer, placing emphasis on the identification and characterization of new antineoplastic drugs that activate different lethal signaling pathways to induce apoptosis, ferroptosis, necroptosis, paraptosis or pyroptosis. Hence the first day will deal with various aspects of oncopharmacology and cancer cell(death) biology.
The second day will focus on immunogenic cancer cell death (ICD), which is a modality of cellular demise stimulating an immune response against dead-cell antigens. Indeed, cytotoxicants are only efficient beyond treatment discontinuation if they succeed in inducing ICD. Hence, most biotech and pharma companies operating in the field of oncology are interested in ICD inducers. One of the major scopes of this day is to compare distinct lethal subroutines with respect to their immunological consequences.
The third day will deal with translational and clinical aspects of immuno-oncology. Ample space will be dedicated to new concepts and ‘omics’ methods (genomics, metabolomics, proteomics, transcriptomics…) allowing to decipher the temporal and spatial organization of therapeutically relevant anticancer immune responses, including those triggered by ICD inducers. This has impact on biomarkers discovery for patient stratification, as well as on the clinical optimization of combination treatments involving ICD-inducing drugs and immune checkpoint inhibitors.
Please ask for the sponsorship opportunities : email@example.com